The
MDM
2 protein plays an important role in the regulation of cell proliferation and apoptosis via ubiquitination and proteasome‐mediated degradation of p53. The genetic polymorphism rs2279744 (c.309T>G) of the
MDM
2
gene is reportedly associated with susceptibility and/or prognosis in various cancers. In this study, we investigated the risk factors for worse survival in patients with lung adenocarcinoma (
AC
). We examined the association between c.309T>G and the prognosis of lung cancer by retrospectively reviewing 453 lung cancer patients. We studied both, clinicopathological and genetic characteristics, including the c.309T>G,
p53
Arg72Pro,
EGFR
,
KRAS
, and
p53
mutations. Associations between these factors and survival outcome were analyzed using Cox proportional hazards models. The frequencies of
MDM
2
polymorphisms were T/T, 20.8%; T/G, 48.6%, and G/G, 30.7%. The overall survival (
OS
) of
AC
patients with pathological stage I disease and the
MDM
2
T/T genotype was significantly shorter than that of those with the T/G or G/G genotypes (
P
= 0.02). Multivariate analysis revealed that the
MDM
2
T/T genotype was an independent, significant prognostic factor (hazard ratio [
HR
] = 2.23; 95% confidence interval [
CI
]: 1.07–4.65;
P
=
0.03). The
MDM
2
T/T genotype was predictive of poorer survival in a Japanese population. Genotyping for this polymorphism might predict the clinical outcomes of stage I
AC
patients.